uniQure N.V. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
uniQure N.V. (QURE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-28.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2024-02-28
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2019-06-30 was 0.00%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-09-30 was 0.00%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-06-30 was 0.00%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-03-31 was 0.00%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2020 was 0.00%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2019 was 0.00%.
- uniQure N.V. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2021-12-31 | 0.00% 10-K · filed 2024-02-28 | |||
| 2020-12-31 | 0.00% 10-K · filed 2021-03-01 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-01 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2019-07-29 | 0.00% 10-Q · filed 2019-07-29 | ||
| 2018-12-31 | 0.00% 10-K · filed 2021-03-01 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-06 | 0.00% 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2019-07-29 | 0.00% 10-Q · filed 2019-07-29 | ||
| 2018-03-31 | 0.00% 10-Q · filed 2018-04-30 | |||
| 2017-12-31 | 0.00% 10-K · filed 2020-03-02 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-06 | 0.00% 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-08 | 0.00% 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | 0.00% 10-Q · filed 2018-04-30 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-02-28 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-01 | 0.00% 10-Q · filed 2017-11-01 | ||
| 2015-12-31 | 0.00% 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |